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Background: Focal ground-glass opacity (GGO) is becoming a major concern because of its
possible association with lung cancer. In this study, we analyzed the long-term progression
of GGOs that persisted for more than 2 years.
Methods: We reviewed focal GGOs identified by thin-section computed tomography that per-
sisted for more than 2 years.
Results: We enrolled a total of 114 patients with 175 GGO lesions. The median patient age was
61 years (range, 37e92 years) and 42 (36.8%) patients were male. Mean initial GGO size was
7.8  4.4 mm. Median follow-up duration was 45 months. Forty-six (26.3%) GGOs had signifi-
cant size increases (2 mm in the longest diameter) with a mean volume doubling time of
1041 days. In a multivariate analysis, large size (10 mm), the presence of a solid portiont of Internal Medicine, Seoul National University Bundang Hospital, 166 Gumi-Ro, Bungdang-Gu,
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Natural course of ground-glass opacity 905(mixed GGO) and old age (65 years) were risk factors for significant size increase, with odds
ratios (95% CI) of 6.46 (2.69e15.6), 2.69 (1.11e6.95) and 2.55 (1.13e5.77), respectively. GGOs
with character changes from pure to mixed or mixed to solid showed more rapid volume expan-
sion.
Conclusions: GGOs which persisted for several years showed an indolent course. Large lesions
with a solid portion and GGOs in male or elderly individuals may be cause for more concern, as
these factors were associated with size increase. Resection should be considered if GGOs show
character changes, as these may be associated with rapid size progression.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
As a result of the recent expansion in the availability of
computed tomography (CT),1e4 focal ground-glass opacity
(GGO) has become a major concern, due to an increase in
detection.5 GGO lesions cannot be ignored, as they are
frequently associated with lung cancer.6e11 Given the ma-
lignant potential of GGO, patients are often subjected to
short interval CT; however, such management is not
reasonable, considering the cumulative radiation associ-
ated with frequent CT12 and the indolent course of most
GGOs.13 Furthermore, some GGOs show no progression over
the course of several years.14 For those cases, resection
may not be necessary, even if malignancy is suggested. A
universal and appropriate follow-up plan for GGO patients
is still under debate, and no surveillance guidelines have
existed until recently.
When focal GGO lesions with malignant potential are
identified, physicians recommend either resection or close
observation. Larger GGOs and/or those with solid compo-
nents are typically resected, whereas small and/or non-
solid lesions are subject to short interval follow-up.15,16
Some GGOs remain persistent for several years without
the need for resection, which can cause concern for phy-
sicians, as it is unknown whether or not these lesions will
progress to incurable malignancies. Therefore, it is imper-
ative to understand the natural course of GGOs. Only a few
reports have been published on this subject. The doubling
time for mixed GGOs has been reported to be greater than 1
year.17 Only a fraction of persistent GGOs demonstrate
rapid size progression, which is evident several months or
years after detection.18 The typical course for a GGO ap-
pears to be indolent; however, definite evidence of the
long-term natural history of GGOs is lacking.
Previously, we reported the short-term natural course of
GGOs.19 In this study, we analyzed the long-term course
and progression of GGOs persistent for more than 2 years
without resection. We also sought to elucidate the risk
factors for size increases of lesions to help inform proper
management.Patients and methods
Patients
We enrolled patients with GGO lesions that were confirmed
by thin-section CT (slice size 1e3 mm) and were persistent
for more than 2 years without resection between April,2004, and July, 2011, at Seoul National University Bundang
Hospital in Seoul, Korea. GGO lesions that were only
detected by low-dose CT or disappeared within 2 years
were excluded from this study. GGO lesions were identified
on CT images by experienced pulmonologists, and size
changes and characters were defined by consensus of a
pulmonologist and experienced radiologists. Follow-up pe-
riods were from the date of the initial CT scan until the last
CT scan still showing the GGO lesion. The study protocol
was reviewed and approved by the Institutional Review
Board of Seoul National University Bundang Hospital
(B-1110/138-109).
Radiologic features of GGO lesions
GGO lesions were classified as pure GGO (pGGO) or mixed
GGO (mGGO) at initial detection, according to the presence
of a solid component within the nodule by thin-section CT
at a lung window setting. GGO size was defined by its
longest diameter. Size increases of 2 mm or more were
considered significant, as changes < 2 mm are subject to
measurement error.16 Volume changes were estimated by
the cube of the longest diameter.
CT scans were performed using various instruments,
including the Brilliance-64, MX-8000 IDT, and iCT 256 (Phi-
lips Medical Systems, Cleveland, OH, USA). Scanning was
performed from the thoracic inlet to the upper portion of
the kidneys. Images were obtained using a level of 600
Hounsfield units (HU) and width of 1500 HU (lung window)
and a level of 30 HU and a width of 400 HU (mediastinal
window). Conventional CT images were reconstructed into
3 mm section thickness, and high-resolution CT images
were reconstructed into 1 mm section thickness.
Pathological examination
Resected surgical specimens were cut at 3 mm intervals and
fixed in 10% buffered formalin. After fixation, all sections
were embedded in paraffin and stained with hematoxylin
and eosin for histologic examination. All sections of tumors
and suspicious lesions were submitted for microscopic
examination. Histopathologic diagnoses were based on
the 2011 adenocarcinoma IASLC/ATS/ERS classification
system.20
Statistical analyzes
The relationship between clinical characteristics and in-
creases in GGO size was evaluated using the c2 test for
906 S.W. Lee et al.categorical variables and logistic regression analysis for
continuous variables. Time to GGO growth was also
analyzed using a Cox’s proportional hazard model. In the
multivariate analysis, the backward selection method was
used to exclude multicollinearity. Volume increases were
compared by Student’s t-test or analysis of variance. Sta-
tistical significance was defined as a two-tailed p value of
<0.05. All data are presented as mean  standard devia-
tion. All statistical analyzes were conducted using PASW
software (v18.0; SPSS, Inc., Chicago, IL, USA).
Results
Demographic characteristics
A total of 175 GGO lesions in 114 patients were included in
our analysis. Median patient age was 61 years (range,
37e92 years) and 42 (36.8%) patients were male (Table 1).
The condition of initial detection was most often at routine
checkup (84/175, 48.0%), followed by evaluation for res-
piratory symptoms (40/175, 22.9%), and regular follow-up
for lung cancer or other nodule (27/175, 15.4%). Median
follow-up time after initial detection was 45 months (range,
24e99 months). Of the 175 GGOs, 143 (81.7%) were pGGO
and 32 (18.3%) were mGGO, initially. Mean GGO size was
7.8  4.4 mm on initial detection, with mean mGGO and
pGGO sizes of 11.2  6.5 mm and 7.0  3.4 mm, respec-
tively (p < 0.001). Twenty-eight patients had a history of
lung cancer, including 22 (78.6%) GGOs and 6 (21.4%) solid
tumors. All of these previous cancer lesions were resected
and pathologically confirmed as adenocarcinoma.
Progression of GGO lesions
Forty-six (26.3%) GGOs showed significant increases in size
(2 mm) during the follow-up period. Twenty-eight (19.6%)
of 143 pGGOs and 18 (56.3%) of 32 mGGOs had significantTable 1 Baseline characteristics of enrolled patients.
Character n Z 114
Age, years; median (range) 61 (37e92)
Male sex, n (%) 69 (60.5)
Smoking history, n (%)
Never smoker 63 (55.3)
Former smoker 26 (22.8)
Current smoker 25 (21.9)
GGO lesion per a patient, n (range) 1 (1e4)
Previous lung cancer, n (%) 28 (24.6)
GGO 22 (78.6)
Solid 6 (21.4)
Initial GGO size (mm), mean  SD
(range)
7.8  4.4 (2.5e31.0)
Initial character of GGO, n (%) 175 (100)
Pure 143 (81.7)
Mixed 32 (18.3)
Follow-up duration, mo; median
(range)
48 (24e99)
GGO, ground-glass opacity.size increases. Eleven pGGOs (7.7%) changed to mGGOs
during follow-up, nine (81.8%) of which had significant size
increases. Three mGGOs increased significantly in size and
became solid masses. There was no difference in the length
of follow-up between GGOs with and without size increases
(48.8  19.4 mo versus 51.5  20.9 mo, respectively,
p Z 0.44). Most GGOs, even those with significant size in-
creases, showed an indolent course and linear increases in
diameter. The mean size increase rate of the 45 GGOs that
showed significant increases was 2.2  2.9 mm/yr. Only
three (2.2% of total GGOs) mGGOs had size increase rates of
>5 mm/yr at least once during the 7 year follow-up period
(Fig. 1). Among 45 GGOs with significant size increases
(27 pGGOs and 18 mGGOs), the size increase rate and vol-
ume doubling time were not different according to their
initial character (pGGO, 1.8  2.3 mm/yr and 872  649
days versus mGGO, 2.6  4.1 mm/yr and 1005  732 days;
p Z 0.35 and p Z 0.19, respectively). A total of 29 lesions
were pathologically confirmed, including 11 (37.9%) inva-
sive adenocarcinoma (ADC), 11 (37.9%) minimally invasive
adenocarcinoma (MIA), three (10.3%) adenocarcinoma in
situ (AIS, formerly known as bronchioloalveolar carcinoma),
one (3.4%) atypical adenomatous hyperplasia (AAH), one
(3.4%) pleomorphic carcinoma, and two (6.9%) interstitial
fibrosis.20 Most mGGOs were MIA or invasive adenocarci-
noma, whereas pGGOs included various pathologic types
(Table 2). Twenty (80%) of 25 adenocarcinoma (in situ)
showed size increase, as did one pleomorphic carcinoma
and one AAH.
A total of 90 GGOs were tracked for more than 4 years,
with a median follow-up time after 4 years of 13 months
(range, 1e51 months). Among these, 25 (27.8%) had size
increases during the total follow-up period, but only two
(2.2%) had a significant size increase after 4 years, except
four GGOs without follow-up for several years. Thirteen
GGOs were confirmed as adenocarcinoma (including two
AISs, five MIAs, and six invasive ADCs). Eleven of them had
significant size increases, but one invasive ADC and one AIS
demonstrated no size increase for as long as 57 and 72
months, respectively.
Risk factors for GGO size increase
According to univariate analysis, age, male sex, larger
initial lesion size, mGGO, bubble lucency (pseudocavitationFigure 1 Progression of 45 GGOs with significant size in-
creases (2 mm).
)Three GGOs with size increase of more than 5 mm/yr at least
once.
Table 2 Pathologic findings from resected GGOs accord-
ing to preoperative radiologic findings.
Pathology, n (%) Radiologic finding Total
Pure GGO Mixed GGO
Benign 0 (0) 2 (100.0) 2
Atypical adenomatous
hyperplasia
1 (100.0) 0 (0) 1
Adenocarcinoma in situ 2 (66.7) 1 (33.3) 3
Minimally invasive
adenocarcinoma
3 (27.3) 8 (72.7) 11
Invasive adenocarcinoma 3 (27.3) 8 (72.7) 11
Other malignancy 0 (0) 1 (100.0) 1
Total 9 20 29
Natural course of ground-glass opacity 907associated with nodules of varying density),21e23 and
smoking history (10 pack years) were significant risk fac-
tors for GGO size increase. Meanwhile, follow-up duration,
previous lung cancer history, and multiple GGOs were not
associated with size increase (Table 3). Initial large size
(10 mm), mGGO and old age remained significant risk
factors for significant size increase (adjusted odds ratio
[95% CI] Z 6.46 [2.69e15.6], 2.69 [1.11e6.95] and 2.55
[1.13e5.77], respectively), in a multivariate analysis usingTable 3 Relationship between initial character and significant
Number n Z 175 Significant s
n Z 45 (%)
Sex
Female 71 9 (12.7)
Male 104 36 (34.6)
Age
<65 114 21 (18.4)
65 61 24 (39.3)
Initial size
<10 mm 137 21 (15.3)
10 mm 38 24 (63.2)
GGO character
Pure GGO 142 27 (19.0)
Mixed GGO 33 18 (54.5)
Bubble lucency
Absent 161 36 (22.4)
Present 14 9 (64.3)
Smoking history
<10PY 119 22 (18.5)
10PY 56 23 (41.1)
Multiplicitya
Multiple 108 25 (23.1)
Single 67 20 (29.9)
Lung cancer history
Absent 122 32 (26.2)
Present 53 13 (24.5)
Follow-up duration
<4 years 85 20 (23.5)
4 years 90 25 (27.8)
GGO, ground-glass opacity; PY, pack year.
a Defined as when more than one GGO was present at the same timthe covariates age, sex, initial size, mGGO, smoking his-
tory, bubble lucency and previous lung cancer history.
Bubble lucency, previous lung cancer and smoking history
were excluded from our final analysis due to multi-
collinearity (Table 4). In a Cox’s proportional hazard model,
mGGO, initial size (10 mm) and single lesion (compared
with multiple lesion) were significant factors for size in-
crease (adjusted hazard ratio Z 3.13 [95% CI, 1.58e6.20],
2.06 [95% CI, 1.08e3.92] and 2.88 [95% CI, 1.41e5.88],
respectively). When we stratified GGOs into the three
groups, pGGO (nZ 134), mGGO (nZ 27), and change from
pGGO to mGGO or mGGO to solid mass (nZ 14), the latter
group demonstrated the fastest volume expansion (Fig. 2,
p < 0.001).Discussion
This study was designed to characterize the natural course
of GGOs that were present, but not resected, for several
years in real practice. According to our enrollment criteria,
we collected distinct GGOs that initially appeared indolent
then undertook image follow-up for several years without
resection. Chest physicians typically identify these lesions
in the clinic, but treatment management plans, including
CT interval and resection, can be somewhat arbitrary andsize increase (2 mm).
ize increase Odds ratio (95% CI) p value
1.00 (reference) 0.002
3.64 (1.62e8.17)
1.00 (reference) 0.003
2.87 (1.43e5.78)
1.00 (reference) <0.001
9.47 (4.23e21.2)
1.00 (reference) <0.001
5.11 (2.29e11.4)
1.00 (reference) 0.002
6.25 (1.97e19.8)
1.00 (reference) 0.002
3.07 (1.52e6.22)
1.00 (reference) 0.33
1.41 (0.71e2.81)
1.00 (reference) 0.81
0.91 (0.43e1.92)
1.00 (reference) 0.52
1.25 (0.63e2.47)
e.
Table 4 Risk factors for GGO lesion size increase.
Multivariate analysis
Adjusted OR
(95% CI)
p value
Initial size 10 mm 6.46 (2.69e15.6) <0.001
Presence of solid portion
(mixed GGO)
2.69 (1.11e6.95) 0.03
Age 65 2.55 (1.13e5.77) 0.03
Male sex 2.43 (0.96e6.15) 0.06
GGO, ground-glass opacity; PY, pack year.
908 S.W. Lee et al.differ according to the physician. In this study, we sought to
guide appropriate treatment plans for GGO lesions. We
found that a small portion (26.3%) of GGOs showed size
increases during a relatively long follow-up period (median,
48 months). Most GGOs, however, displayed an indolent
course, and only three had relatively rapid size increases
(>5 mm/yr). The presence of a solid portion (mGGO), male
sex, large size, and old age were risk factors for size in-
creases, but pGGO also showed rapid volume expansion if it
changed to mGGO.
In a previous study, mGGO, old age, and large lesion size
were associated with size increases of GGOs in a univariate
analysis; male sex was also associated with marginal sig-
nificance.16 This is similar to the findings of our study;
however, the results of the multivariate analyzes were
somewhat different, as the previous study found history of
lung cancer as a significant risk.16 In our study, initial GGO
size was also associated with size increase, but our findingFigure 2 Volume increase per 2 years, according to GGO
character.
)pGGO to mGGO or mGGO to solid mass.of age and sex as factors have not been reported previously.
Male sex showed marginal significance in for size increase.
One possible explanation is the different presentation of
GGO by sex. A previous study reported that adenocarci-
noma is more prevalent in males and AAH more prevalent in
females.6 In our study, the proportion of mGGOs was
slightly greater in males, although it did not reach statis-
tical significance (21.2% versus 14.1%, p Z 0.32). Old age
was also an independent risk factor for size increase. It is
not easy to explain this observation; GGOs in younger pa-
tients seem to have a relatively indolent course, due to
lead-time bias and they can progress in old age. Some
previous studies reported that bubble lucency was associ-
ated with malignancy.21 Bubble lucency was also associated
with significant size increase in univariate analysis in this
study; however, it was also associated with mGGO
(p Z 0.001) and thus excluded from the multivariate
analysis due to multicollinearity.
We did not find lung cancer history to be a risk factor for
GGO progression. Only 14 (26.4%) of the 53 lesions in 28
patients with a history of lung cancer had significant GGO
size increases. This rate is consistent with the findings of
previous studies.14,16 Size is a suggested predictor of ma-
lignancy,24 and we determined that the initial mean GGO
size in patients with lung cancer history was 7.4  5.2 mm;
only nine (17.0%) patients had GGO lesions 10 mm. The
small size of GGOs in patients with a history of lung cancer
may explain the indolent course. Multifocal GGOs arise as
independent events rather than by intrapulmonary spread
or systemic metastasis.25 Therefore, operable lung cancer
should be considered for resection, even when other GGO
sites are difficult to resect at the same time. Regular
follow-up is sufficient for those GGOs, especially when the
lesion is small. This recommendation is supported by one
report stating that the prognosis of GGO is favorable.26 In
our study, only one patient, who went without follow-up for
several years, died due to a GGO.
GGO lesions with character changes from pGGO to
mGGO, or mGGO to solid showed rapid size increases.
Atypical adenomatous hyperplasia has been reported to be
the precursor of adenocarcinoma.27,28 Therefore, character
changes of pGGOs may indicate rapid progression from AAH
to adenocarcinoma. GGO lesions with significant size in-
creases were more prevalent in mGGO than pGGO. A recent
report based on screening low-dose CT also indicated that
new development of an internal solid portion was signifi-
cantly nodule growth.29
AAH and AIS typically appear as pGGOs; those of AIS are
usually slightly larger and have higher attenuation than the
very faint GGOs of AAH.30,31 MIA has a variable32,33 and not
yet fully understood pathology. Invasive adenocarcinoma
is usually a solid nodule, but may also present as a
GGO.14,34,35 In our study, resected pGGO had a variety of
pathologic diagnoses including AAH, AIS, MIA, or invasive
adenocarcinoma. Meanwhile, most mGGOs proved to be
MIA or invasive adenocarcinoma. These included only
resected cases. Therefore, small GGOs with an indolent
course were excluded from the analysis, which may explain
the small number of AAH and AIS cases. Among invasive
adenocarcinomas, three (27.3%) presented as pGGO, two of
which contained bubble lucency. These results indicate an
overlap among the imaging features of GGOs.
Natural course of ground-glass opacity 909Decisions regarding CT intervals and the termination of
CT follow-up are challenging and important issues.
Although most GGO lesions did not increase in size after 4
years in this study, 13 (including six invasive ADCs) were
diagnosed as adenocarcinoma. Predictions of whether such
adenocarcinomas will develop into clinically meaningful
malignant lesions are difficult. Some reports have sug-
gested that pulmonary nodules can be generally considered
benign if they maintain their size over a 2-year observation
period.36,37 However, this assumption cannot be applied to
GGOs, as one GGO lesion without a size increase for 57
months in our study was later confirmed as invasive ADC.
Rapid progression was also noted in two GGO lesions
without follow-up for several years. Therefore, regular CT
follow-up, for example, yearly, should be continued for an
indefinite period, until longer-term data can be obtained.
Resection or shorter CT intervals, such as 6 months, should
be considered when a pGGO develops a solid component,
which can suggest rapid size progression. Longer follow-up
CT intervals, such as 2 years, could be sufficient in the case
of pGGOs with a size <10 mm or no change for more than
4 years, which suggests slow progression and good
prognosis.23,38
Whether or when persistent GGO should be resected is
also controversial. Based on observational data, close
follow-up without resection until the appearance of a solid
component was suggested for pGGO.39 Our data support
this suggestion. Only a small portion of pGGO lesions
(19.6%) showed size increases. Most mGGOs had an indolent
course, and no deaths have been reported due to lung
cancer for those with regular follow-up. Even among GGO
lesions with size increases, the rate of increase was very
slow (2.2  2.9 mm/yr) and their volume doubling time was
more than 2 years. Favorable prognosis and slow progres-
sion have been reported by others.17,34,40,41 Considering the
radiation hazard of CT, indolent course, and favorable
prognosis, annual follow-up with CT may be sufficient for
GGO lesions. However, resection should be considered
when pGGO lesions develop a solid portion, as this may be
associated with rapid progression.
Some studies, including research from our group, report
that GGO lesions can decrease in size or even disappear;
however, shrinkage of GGO lesions usually occurs within 3
months.19,39 Blood eosinophil counts in transient GGO cases
are significantly higher than in GGO cases diagnosed with
cancer.19 This suggests that pulmonary infiltration of eo-
sinophils might be the cause of transient GGOs. No GGO
lesions had a significant size decrease (2 mm) in this
study. This may be attributable to our enrollment criteria,
as we only included individuals with GGOs persistent for
more than 2 years.
This study had limitations. First, this was a retrospective
study, and CT intervals varied among the patients. There-
fore, an accurate size increase rate was hard to estimate.
Second, all enrolled patients were Koreans. Racial and
epidemiologic factors should be considered when interpret-
ing our findings. Third, although lesion size increase was
used as the main outcome measure, invasive cancer or car-
cinoma may be a more appropriate outcome. In this study,
only 29 (16.6%) lesions were confirmed pathologically and
most of them (26 [89.6%]) were adenocarcinoma (in situ).
Therefore, it was not possible to use this as a measure ofoutcome. We considered that size increase was at least as, if
not more, important as pathology in real clinical practice,
because even adenocarcinoma may not progress for several
years, as proven in this study. Finally, it is possible to classify
GGOs in a different way, which may have permitted a more
detailed analysis.41,42 However, we chose a method used in
previous reports16,20,24,25 to simplify the results and to
maintain statistical power.
In conclusion, a significant fraction of GGO lesions
persistent for more than 2 years progressed slowly. How-
ever, larger GGOs with a solid component observed in males
or older patients may be cause for more concern and closer
follow-up, as these were risk factors for lesion size in-
crease. If GGO lesions show character changes, such as
from pure to mixed, early resection should be considered,
as it may indicate rapid progression in size.Conflict of interest statement
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